New Blue Biology Lecture: Research Progress of Novel Anti-Tumor Antibody/Ligand Conjugated Drugs

Hangzhou NewBlue and researcher Pan Liqiang from the School of Pharmacy, Zhejiang University will hold an online lecture on the research progress of new anti-tumor antibody/ligand conjugated drugs from 14:00-15:00 pm on August 25, 2022.

Since the FDA approved the first monoclonal antibody drug in 1986, antibody drugs have accounted for nearly one-fifth of FDA new drug approvals each year

Surface plasmon resonance (SPR) technology is an indispensable technology for the detection of antigen and antibody affinity/kinetics.

Lecture Agenda

Theme one:

Research progress of novel antitumor antibody/ligand conjugated drugs

abstract:

1.

2.

3.

4.

5.

6.

7.

Speaker introduction:

Liqiang Pan | Researcher, School of Pharmacy, Zhejiang University

Engaged in research on new biotech drugs related to tumor immunity, immune receptor activation mechanism, and high-throughput screening and optimization of precise tumor-targeting antibodies, and is committed to using multispecific biological drugs to precisely regulate immune cell activity and local immune system.

Theme two:

How to detect the affinity of antibody drug and target protein by SPR technology

abstract:

1 Introduction to SPR Technology

2 SPR experimental process and scheme design

3.

Speaker introduction:

Wang Pengjuan | Hangzhou Newland Application Technical Support

Engaged in SPR experiments and application development, with 5 years of experience in SPR molecular interaction experiments, good at SPR molecular interaction experimental method development and scheme design

Registration channel

Scan the code to follow us